Neutrophil-to-Lymphocyte Ratio Predicts Infusion-Site Skin Nodules in Parkinson Disease Patients Receiving Foslevodopa/Foscarbidopa Subcutaneous Infusion

This study demonstrates that a higher baseline neutrophil-to-lymphocyte ratio (NLR) serves as a predictive biomarker for the development and persistence of infusion-site skin nodules in Parkinson's disease patients receiving foslevodopa/foscarbidopa subcutaneous infusion, while multidisciplinary surveillance effectively mitigates treatment discontinuation despite these adverse events.

The Gist

Imagine you have a garden hose (the medication pump) that you need to leave plugged into your skin for weeks or months to water your plants (treat Parkinson's disease). Usually, this works great. But sometimes, the spot where the hose connects gets angry. It swells up, gets red, and forms a hard lump called a "nodule." If these lumps get too big or painful, people have to unplug the hose and stop the treatment, which is a big problem.

This paper is like a detective story about why some people's skin gets angry at the hose while others stay calm, and how a simple blood test might predict who is at risk.

Here is the story broken down into simple parts:

1. The Mystery: Why do some skins get "angry"?

The doctors noticed that when patients started using this new continuous infusion pump (Foslevodopa/Foscarbidopa), about 42% of them developed these annoying skin lumps within the first three months.

The researchers wondered: Is it just bad luck? Or is there something inside the patient's body that makes their skin more sensitive?

They looked at the patients' blood, specifically at two types of white blood cells:

• Neutrophils: The body's "first responders" or "firefighters" that rush to a scene to fight infection or injury.
• Lymphocytes: The "peacekeepers" or "managers" that help calm things down and heal the wound.

They calculated a score called the NLR (Neutrophil-to-Lymphocyte Ratio). Think of this as a traffic light for inflammation:

• High NLR: Too many firefighters rushing in and not enough managers to tell them to stand down. The body is in a state of high alert.
• Low NLR: A balanced team where the firefighters and managers work together smoothly.

2. The Discovery: The "Red Flag" in the Blood

The study found a clear pattern:

• Patients who developed the painful skin lumps had a High NLR before they even started the treatment. Their bodies were already in a state of "high alert."
• Patients who didn't get lumps had a Low NLR. Their immune systems were more balanced.

It's like finding out that people who get sunburned easily have a specific type of skin that reacts strongly to the sun, even before they step outside. If you know someone has a "High NLR" (a high inflammation score), you know they are more likely to get a reaction to the pump.

3. The Solution: A "Concierge" Team Saves the Day

Usually, when these skin lumps happen, people quit the treatment. In other studies, up to 25-40% of people had to stop because the skin got too irritated.

But in this study, only 5.3% of people stopped. Why? Because the doctors didn't just wait for the problem to happen; they acted like a high-end concierge team.

• The Team: A neurologist and a specialized nurse worked together.
• The Plan: They taught patients exactly how to rotate the spot where the needle goes (like changing the spot where you put a heavy backpack on your shoulder so it doesn't hurt).
• The Monitoring: Patients could send photos of their skin via email or phone. If a lump started to form, the team treated it immediately with creams or antibiotics before it got bad.

The Analogy: Imagine a leaky roof. Most people wait until the ceiling collapses before calling a plumber. This team put a bucket under the leak, fixed it immediately, and kept the roof from ever collapsing.

4. The Takeaway: What does this mean for you?

This research gives us two big tools:

1. A Crystal Ball (The Blood Test): By checking the NLR blood test before starting the pump, doctors can predict who is at high risk for skin lumps. If your "traffic light" is red (High NLR), the doctor knows to be extra careful, maybe check your skin more often, or start preventive treatments right away.
2. The Power of Care: Even if you are at high risk, you don't have to quit the treatment. With a dedicated team watching over you and managing the skin issues quickly, you can keep the therapy going.

In a nutshell:
Some people's immune systems are like over-enthusiastic guards that get too excited by the needle and cause a fuss (skin lumps). We can spot these "over-enthusiastic guards" with a simple blood test. And if we have a good team to manage the situation, we can keep the peace and let the medicine do its job without stopping.

Technical Summary

1. Problem Statement

Continuous subcutaneous foslevodopa/foscarbidopa infusion (LDp/CDp-CSI) is an effective therapy for advanced Parkinson's disease (PD) to manage motor fluctuations. However, a significant barrier to long-term adherence is the development of infusion-site skin nodules (PD-CSN). These reactions, ranging from erythema to painful induration, lead to treatment discontinuation in up to 25–44% of patients in previous cohorts. While local management strategies exist, the underlying systemic biological predictors for who will develop these nodules remain unidentified. The study hypothesizes that systemic inflammation, specifically reflected by the Neutrophil-to-Lymphocyte Ratio (NLR), predisposes patients to local cutaneous intolerance.

2. Methodology

• Study Design: A prospective, observational, single-center study conducted at the Parkinson Institute of Milan, Italy.
• Cohort: 38 patients with idiopathic PD initiating LDp/CDp-CSI between February 2024 and June 2025.
  • Exclusion criteria: Acute infection, autoimmune disease, malignancy, or recent immunosuppressive therapy.
• Intervention & Management:
  • Patients underwent a standardized 3–5 day inpatient titration and education program.
  • Multidisciplinary Surveillance: A structured care model involving neurologists and nurse specialists included remote monitoring, strict site rotation, aseptic techniques, and rapid response to skin changes (topical steroids, antibiotics, or site rotation).
• Data Collection:
  • Baseline: Peripheral blood sampling for neutrophil and lymphocyte counts to calculate NLR. Clinical assessments included UPDRS-III, Hoehn & Yahr, and cognitive screening (MoCA, FAB, MMSE).
  • Follow-up: Assessments at 3, 6, and 12 months.
  • Nodule Classification: Blinded raters (neurologist and nurse) classified nodules. For analysis, they were dichotomized into Clinically Significant Nodules (PD-CSN) vs. No Significant Reactions (PD-NSR).
• Statistical Analysis:
  • Group comparisons (t-test/Mann-Whitney).
  • ANCOVA: To adjust for covariates (age, sex, BMI, MoCA, FAB, LEDD).
  • ROC Analysis: To determine the discriminatory power of NLR.
  • Survival Analysis: Kaplan-Meier curves and Log-rank tests to assess time-to-event (nodule onset) based on NLR groups.

3. Key Contributions

1. Identification of a Predictive Biomarker: The study establishes baseline NLR as a significant predictor for the development and persistence of infusion-site nodules in PD patients.
2. Mechanistic Insight: It links systemic inflammatory status (neutrophil activation and lymphocytic dysregulation) to local cutaneous pathology, suggesting that "inflammaging" and immune dysregulation in PD contribute to poor skin tolerance.
3. Validation of a Care Model: The study demonstrates that a multidisciplinary, proactive surveillance protocol can drastically reduce treatment discontinuation rates (down to 5.3%) despite a high incidence of nodules (42%).
4. Clinical Stratification Tool: It proposes a specific NLR cut-off (≥2.05) to identify high-risk patients for early intervention.

4. Key Results

• Incidence: At 3 months, 42% of patients (16/38) developed clinically significant nodules (PD-CSN).
• Immunological Differences:
  • At 3 Months: PD-CSN patients had significantly higher baseline neutrophil counts ($P=0.030$) and NLR ($P=0.007$) compared to PD-NSR.
  • ANCOVA: NLR remained independently associated with nodule status after adjusting for age, sex, BMI, and cognitive scores ($F=7.06, P=0.012$).
  • At Long-term Follow-up (Mean 11 months): PD-CSN patients showed significantly lower lymphocyte counts ($P=0.002$) and higher NLR ($P=0.001$).
• Predictive Performance:
  • ROC Analysis: NLR showed acceptable discrimination for PD-CSN at 3 months (AUC = 0.73, $P=0.016$) and excellent discrimination at long-term follow-up (AUC = 0.875, $P=0.001$).
  • Optimal Cut-off: An NLR $\ge$ 2.05 yielded 62.5% sensitivity and 86.4% specificity.
• Survival Analysis: Patients with high baseline NLR developed nodules significantly earlier (median 6 months) compared to the low NLR group (median 14.22 months) ($P=0.001$).
• Discontinuation Rate: Despite the high incidence of nodules, only 5.3% of patients discontinued therapy, attributed to the effective multidisciplinary management protocol.
• Clinical Correlates: PD-CSN patients had lower BMI and lower cognitive scores (MoCA/FAB), suggesting cognitive fragility and lower subcutaneous tissue thickness may be secondary risk factors.

5. Significance and Implications

• Clinical Utility: NLR is a low-cost, readily available blood marker. Identifying patients with high baseline NLR allows clinicians to stratify risk, potentially initiating more aggressive prophylactic skin care or closer monitoring for these individuals.
• Therapeutic Adherence: The study highlights that infusion-site reactions are manageable. The low discontinuation rate (5.3% vs. historical 25–44%) proves that structured education and multidisciplinary follow-up are critical to sustaining LDp/CDp-CSI therapy.
• Pathophysiological Understanding: The findings suggest a dual-phase immune mechanism: an initial neutrophil-driven inflammatory response followed by a lymphocyte-mediated failure to resolve inflammation, leading to chronic nodules.
• Future Directions: The authors call for future studies incorporating cytokine profiling, immune phenotyping, and skin histology to validate these mechanisms and refine personalized management strategies.

Limitations: The study is limited by a small sample size (38 patients), lack of histopathological confirmation, and its single-center nature. However, the rigorous statistical adjustments and blinded assessment strengthen the validity of the findings.